American Society of Hematology (ASH), 2022


  1. Prophylactic Corticosteroid Use with Axicabtagene Ciloleucel (Axi-Cel) in Patients (Pts) with Relapsed/Refractory Large B-Cell Lymphoma (R/R LBCL): 2-Year Follow-Up of ZUMA-1 Cohort 6
  2. 3-Year Follow-Up Analysis of ZUMA-5: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients With Relapsed/Refractory (R/R) Indolent Non-Hodgkin Lymphoma (iNHL)
  3. Outcomes of Subsequent Anti-Lymphoma Therapies in Patients (Pts) With Large B-Cell Lymphoma (LBCL) Treated With Axicabtagene Ciloleucel (Axi-Cel) or Standard of Care (SOC) in the Second-Line (2L) ZUMA-7 Study
  4. Association of Metabolic Tumor Volume (MTV) and Clinical Outcomes in Second-Line (2L) Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL) Following Axicabtagene Ciloleucel (Axi-Cel) Versus Standard-of-Care (SOC) Therapy in ZUMA-7
  5. ZUMA-19: A Phase 1/2 Study of Axicabtagene Ciloleucel Plus Lenzilumab in Patients With Relapsed or Refractory Large B-cell Lymphoma
  6. Identification of IL-4 as a Key Regulator of CAR T-cell Exhaustion Using Functional Genomics and Correlates of the Zuma-1 Clinical Trial
  7. Baseline CRP and Ferritin Identify Patients at High Risk of Poor Outcomes after Axicabtagene Ciloleucel Despite Corticosteroid Prophylaxis
  8. Hospital Costs and HCRU CAR T-Cell Therapy and Hematopoietic Cell Transplant (HCT) in Patients with LBCL in the US
  9. Network Meta-Analysis (NMA) of CART-Cell Therapy for the Treatment of r/r DLBCL after 2 Prior Treatments using Published Comparative Studies
  10. Cost-effectiveness of axi-cel for adult patients with relapsed or refractory follicular lymphoma in the United States
  11. A 3-Year Follow-up Comparison of Clinical Outcomes from ZUMA-5 (Axicabtagene Ciloleucel) and the International SCHOLAR-5 External Control Cohort in Relapsed/Refractory Follicular Lymphoma (R/R FL)
  12. Real-World Patient-Reported Outcomes among Recipients of Axicabtagene Ciloleucel for R/R LBCL
  13. The Real-World Use of Bridging Therapy (BT) in Relapsed or Refractory LBCL Patients Treated with CAR T-cell Therapy: A Systematic Literature Review
  14. Patients of Minority Race or Ethnicity in the US Receiving CAR T-cell Therapy in Clinical Trials and in the Real-world: A SEER-based Simulation
  15. Real-world Impact of Time from Leukapheresis to Infusion (Vein-to-Vein Time) in Patients with r/r LBCL Treated with Axi-cel
  16. Outcomes of axicabtagene ciloleucel in comparison with chemoimmunotherapy (CIT) in an elderly population for treatment of relapsed or refractory (r/r) large B cell lymphoma (LBCL) after two or more lines of prior therapy
  17. Assessment of Durable Responses After Brexucabtagene Autoleucel (KTE-X19) in the ZUMA-2 Study in Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL)
  18. A Phase 1 Study of KTE-X19, an Anti-CD19 Chimeric Antigen Receptor (CAR) T-cell Therapy, in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia
  19. Immunosuppressive monocyte modulation of CAR T cell functions and impact on response to CART19
  20. A Comparison of Overall Survival with Brexucabtagene Autoleucel (Brexu-cel) CAR T-Cell Therapy (ZUMA-2) and Standard of Care (SCHOLAR-2) in Patients with Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL) Previously Treated with a Covalent Bruton Tyrosine Kinase Inhibitor (BTKi)
  21. Chimeric Antigen Receptor T-Cell Therapy Setting of Care: A Retrospective Cohort Analysis of MCL and FL Patients in the US
  22. Updated Outcomes From the Historical Control Study SCHOLAR-3 Contextualizing ZUMA-3 Results of Brexucabtagene Autoleucel (KTE-X19) in Adult Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia (R/R B-ALL)